Sort
8,912 grants matching “sars cov 2”
New Paradigms for Ribosome Recoding in (+)Strand Viruses
$222,637Anne Elizabeth Simon · Univ Of Maryland, College Park · R21 · FY2015 · AI
Prospective predictors of risk and resilience trajectories of mental health in US youth during COVID-19
$222,500Ran Barzilay · Children'S Hosp Of Philadelphia · R21 · FY2024 · MH
Building a Toolbox to Study the SARS-CoV-2 Proteome
$222,329Brian Kenneth Kay · Tango Biosciences, Inc. · R43 · FY2021 · AI
Community-Academic Partnerships to Address COVID-19 Inequities within African American Communities
$222,198Tiarney D Ritchwood · Duke University · DP2 · FY2021 · MD
Inflammatory Response and SARS Pathogenesis: An in vitro Model
$222,197Chien-Te K Tseng · University Of Texas Med Br Galveston · R21 · FY2009 · AI
Inflammatory Response and SARS Pathogenesis: An in vitro Model
$222,197Chien-Te K Tseng · University Of Texas Med Br Galveston · R21 · FY2008 · AI
Anti-inflammatory activity of hydrogels designed to capture extracellular inflammasomes
$222,189Eva De Alba Bastarrechea · University Of California, Merced · R21 · FY2023 · AI
Drug Repurposing Screening for HIV and Other Viruses
$222,049Catherine Chen · National Center For Advancing Translational Sciences · ZIA · FY2025 · TR
AI-Based Modeling and Drug Development
$222,049Wei Zheng · National Center For Advancing Translational Sciences · ZIA · FY2025 · TR
Extracellular vesicles encapsulating CRISPR machinery for treatment of SARS-CoV-2 infection
$221,972Houjian Cai · University Of Georgia · R21 · FY2023 · AI
Myeloid cell TRAF6 signaling in SARS-CoV-2-induced dysregulated lung immunity
$221,919Rudragouda Channappanavar · Oklahoma State University Stillwater · R21 · FY2024 · AI
The Development of Reversible Covalent PROTAC Technology as a New Anti-COVID-19 Strategy
$221,910Shiqing Xu · Texas A&M University · R21 · FY2021 · AI
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
$221,905Ursula Buchholz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
What is the human antibody response to measles virus vaccination?
$221,888Erica Ollmann Saphire · La Jolla Institute For Immunology · R21 · FY2025 · AI
International epidemiology Databases to Evaluate AIDS (IeDEA) Southern Africa.
$221,852Eliane Rohner · Universitat Bern · U01 · FY2025 · AI
Development of PROTACs Targeting Papain-like Protease as Broad-Spectrum Anti-Coronavirus Therapeutics
$221,799Shiqing Xu · Texas A&M University · R21 · FY2022 · AI
CACHET - Pilot Project
$221,761Gokhan M. Mutlu · University Of Chicago · P30 · FY2024 · ES
CACHET - Pilot Project
$221,761Gokhan M. Mutlu · University Of Chicago · P30 · FY2022 · ES
CACHET - Pilot Project
$221,761Gokhan M. Mutlu · University Of Chicago · P30 · FY2023 · ES
Development of methods for highly multiplexed quantification of cancer proteomes using large-scale nanobody libraries
$221,595Nir Hacohen · Broad Institute, Inc. · R61 · FY2023 · CA
Development of methods for highly multiplexed quantification of cancer proteomes using large-scale nanobody libraries
$221,595Nir Hacohen · Broad Institute, Inc. · R61 · FY2025 · CA
Coronavirus capping and its impact on the host metabolism
$221,270Monica Rosas Lemus · University Of New Mexico Health Scis Ctr · P20 · FY2022 · GM
Improving mRNA vaccines with extracellular vesicle-associated immunogens
$221,250Michael R. Farzan · Boston Children'S Hospital · R21 · FY2024 · AI
A Novel Paradigm for the Development of a Peptide Vaccine to Treat KRAS Mutant Cancers
$221,186Albert J. Wong · Stanford University · R21 · FY2021 · CA
Acquisition of a 700 MHz NMR CryoProbe
$221,154Jean S Baum · Rutgers, The State Univ Of N.J. · R35 · FY2021 · GM